Share on StockTwits

Cubist Pharmaceuticals (NASDAQ:CBST) SVP Gregory Stea sold 38,326 shares of the stock on the open market in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $65.88, for a total transaction of $2,524,916.88. Following the transaction, the senior vice president now directly owns 18,136 shares of the company’s stock, valued at approximately $1,194,800. The sale was disclosed in a filing with the SEC, which is available at this link.

A number of research firms have recently commented on CBST. Analysts at Zacks downgraded shares of Cubist Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Monday. They now have a $58.00 price target on the stock. Separately, analysts at JMP Securities downgraded shares of Cubist Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 23rd. They now have a $80.00 price target on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Cubist Pharmaceuticals in a research note on Monday, June 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Cubist Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $79.64.

Shares of Cubist Pharmaceuticals (NASDAQ:CBST) traded down 2.14% during mid-day trading on Wednesday, hitting $64.80. 584,445 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 52-week low of $58.50 and a 52-week high of $82.12. The stock’s 50-day moving average is $64.44 and its 200-day moving average is $69.36. The company has a market cap of $4.907 billion and a price-to-earnings ratio of 580.88.

Cubist Pharmaceuticals (NASDAQ:CBST) last announced its earnings results on Tuesday, July 22nd. The company reported $0.23 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.22. The company had revenue of $294.40 million for the quarter, compared to the consensus estimate of $299.60 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The company’s quarterly revenue was up 13.8% on a year-over-year basis. Analysts expect that Cubist Pharmaceuticals will post $0.71 EPS for the current fiscal year.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.